WEN LEANA 4
4 · UroGen Pharma Ltd. · Filed Jun 24, 2026
Research Summary
AI-generated summary of this filing
UroGen (URGN) Director Wen Leana Receives 18,000 Share Awards
What Happened
Wen Leana, a director of UroGen Pharma Ltd. (URGN), received equity awards on 2026-06-22: a grant of 10,000 option-based shares and 8,000 restricted stock units (RSUs). Both awards were recorded at $0.00 (no cash paid). Together the grants total 18,000 derivative awards that will convert to ordinary shares only as they vest.
Key Details
- Transaction date: 2026-06-22; Form 4 filed 2026-06-24 (timely, not marked late).
- Awards: 10,000 option-based units (derivative) and 8,000 RSUs (derivative); grant price reported $0.00.
- Vesting: both awards vest in equal quarterly installments over one year, subject to Continuous Service (see footnotes).
- RSU note: each RSU represents a contingent right to one ordinary share upon vesting.
- Shares owned after transaction: not specified in the filing.
Context
- These are awards/grants (not open-market purchases or sales). Options give the right to acquire shares in the future; RSUs convert to shares upon vesting.
- Awards issued to directors are common for compensation and retention; they do not by themselves indicate a purchase or sale sentiment.
Insider Transaction Report
Form 4
WEN LEANA
Director
Transactions
- Award
Stock Option (right ot buy)
[F1]2026-06-22+10,000→ 10,000 totalExercise: $34.99Exp: 2036-06-22→ Ordinary Shares (10,000 underlying) - Award
Restricted Stock Unit
[F2][F3]2026-06-22+8,000→ 8,000 total→ Ordinary Shares (8,000 underlying)
Footnotes (3)
- [F1]The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
- [F2]Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
- [F3]The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
Signature
/s/ Jason D. Smith, Attorney-in-Fact|2026-06-23